Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease

Richard L Doty, Matthew B Stern, Cheryl Pfeiffer, Steve M Gollomp, Howard I Hurtig

Abstract

Decreased olfactory function is among the first signs of idiopathic Parkinson's disease (PD). Whether such dysfunction is present to the same degree on both sides of the nose, however, is unknown. Furthermore, whether the deficit results from or is influenced by anti-Parkinsonian medications has not been definitely established. Odour identification ability was evaluated on the left and right sides of the nose in 20 early-stage untreated PD patients, 20 early-stage treated PD patients, and 20 controls. In all cases, the PD related olfactory dysfunction was bilateral and no difference was observed between the test scores of patients taking or not taking drugs for PD. Although asymmetries of unsystematic direction were present in the test scores of some PD patients, similar asymmetries were observed in the controls and the asymmetries were not related to the side of the major motor dysfunction. As in earlier work, no relation was present between the olfactory test scores and the degree of tremor, rigidity, bradykinesia, or gait disturbance at the time of testing. These findings indicate that the olfactory dysfunction of early stage PD is robust, typically of the same general magnitude on both sides of the nose, and uninfluenced by anti-Parkinsonian medications.

School of Medicine,
University of
Pennsylvania,
Philadelphia
Smell and Taste
Center and
Department of
Otorhinolaryngology
R L Doty
C Pfeiffer

Department of
Physiology
R L Doty

Department of
Neurology and
Graduate Hospital
M B Stern
S M Gollomp
H I Hurtig

Correspondence to:
Dr Doty, Director, Smell
and Taste Center, 5 Ravdin
Institute, Hospital of the
University of Pennsylvania,
3400 Spruce Street,
Philadelphia, PA 19104 (215-
662-6580)

Received 25 February 1991
and in revised form
8 July 1991
Accepted 17 July 1991

Decreased ability to smell is present in patients with early-stage Alzheimer's disease,¹⁻⁵ idiopathic Parkinson's disease (PD),⁶⁻¹⁰ and the Parkinsonism-dementia complex of Guam (PDC).¹¹ Although the physiological basis of these decrements is poorly understood, both peripheral and central segments of the olfactory pathways seem to be affected. For example, degenerative changes have been noted in the olfactory epithelium, the olfactory bulb, and the pyriform, prepyriform, and entorhinal cortices of patients with Alzheimer's disease.¹²⁻¹⁹ Although few studies of the neuropathology of the olfactory pathways of PD patients are available, near-total loss of cells within the anterior olfactory nucleus has been described for PDC.²⁰

Recent studies suggest that the olfactory dysfunction of idiopathic PD does not progress significantly over time and is unrelated to

the degree of motor and cognitive symptoms (implying independence from the more dynamic elements of the disease proper).^{6,7} Quantitative testing of only four untreated PD patients, however, has been reported in the literature,¹⁰ and whether the olfactory loss is symmetric or asymmetric is unknown as only bilateral testing has been performed (such testing largely reflects the best functioning nasal chamber).²¹ Given that the olfactory projections have a very large ipsilateral component (possibly explaining why unilateral temporal lobe resection impairs odour identification ability in the nostril ipsilateral to the resected lobe),²² the presence of olfactory asymmetry might provide a marker for hemispheric differences in neurotransmitter function. Functional or anatomical asymmetries of dopaminergic systems have been suggested, on the basis of both neuropsychological and neurochemical findings, to be present in the central nervous system (CNS) of PD patients, although the differences are often subtle.^{23,24}

We studied whether the olfactory disorder of early-stage PD was asymmetric and, if so, whether the asymmetry was correlated with that observed in the motor system. We also compared the olfactory function of early-stage patients taking anti-Parkinsonian medications to that of early-stage patients not taking such medications.

Materials and methods

Subjects

The untreated study group comprised of 20 patients with early PD who were enrolled in the DATATOP clinical trial.²⁵ All of them had never taken or had stopped taking anti-Parkinsonian medications for a period of at least six weeks before olfactory testing. Five were left handed and the remainder right handed. Twenty patients with PD not enrolled in DATATOP who were taking anti-Parkinsonian medications at the time of the study made up the medicated study group, whereas 20 individuals without neurological disease served as normal controls. One of the medicated PD patients was left handed; all of the others and the control subjects were right handed. The three groups were selected to contain patients of similar age, sex, and smoking habits, since these factors are known to influence the olfactory measure used in this study.²⁶⁻²⁹ Within the group taking antiparkinsonian drugs, 19 were

Table 1 Demographics of three study groups in parkinsonism study.

	Untreated patients (n = 20)	Treated patients (n = 20)	Normal controls (n = 20)
Mean (SD) age (years)	61.80 (9.76)	62.05 (10.14)	65.40 (9.66)
Mean (SD) length of education (years)	15.33 (2.63)	13.90 (2.41)	13.55 (2.42)
Male:female ratio	15:5	15:5	15:5
Number of current, previous, never cigarette smokers	1, 9, 10	0, 11, 9	3, 10, 7
Mean (SD) duration of symptoms (years)	2.63 (0.74)	7.43 (3.20)	—
Mean (SD) Hoehn and Yahr stage	1.47 (0.47)	1.55 (0.51)	—

taking Sinemet (l-dopa with carbidopa), either alone (eight patients) or in combination with anticholinergic drugs (such as benztropine) or other dopamine-related drugs (such as amantadine, bromocriptine) or both (11 patients). One patient was taking an anticholinergic drug alone (ethopropazine). The two groups of patients were statistically comparable in terms of age, gender, and smoking habits (table 1). The duration of the disease, however, was much shorter in the untreated than in the treated patients (group $\times$ gender analysis of covariance (ANCOVA) Group F (1,35) = 30.93, $p < 0.001$; covariate = age).³⁰ The mean age of the control group was higher than that of the untreated PD group ($t = 3.60$, $df = 19$, $p = 0.034$), largely because four controls could not be placed within a five year age bracket to their respective PD matches. These differences were of no consequence to the findings of the study, as there was no association between disease duration and the magnitude of the olfactory dysfunction (in concurrence with earlier work);⁶ the direction of the age difference would mitigate against the hypothesis of a PD related deficit in olfactory function²⁷⁻³¹ (which, in fact, was found); and age was used as a covariate in most of the statistical analyses.

Olfactory test procedure

The University of Pennsylvania Smell Identification Test (UPSIT),²⁶ a standardised forced choice test (commercially available as the Smell Identification TestTM, Sensonics, Inc. Haddonfield, NJ) was chosen because of its ease of administration, strong correlations with more time consuming test measures (for example, olfactory thresholds), and high reliability.²⁶⁻³² The details of this test are presented elsewhere.^{26-29, 31, 32} Briefly, each of the 40 pages of this four booklet test contain a microencapsulated ("scratch and sniff") odour and a related four alternative multiple choice question. The subject's task is to provide one of the four indicated answers, even if no smell is perceived (that is, the test is forced choice). The stimuli of this test span a wide range of qualitative odour classes, consist of both single and multiple component odorants, and are familiar and readily identifiable by most people within the context of a multiple-choice response format.²⁶ Two booklets (20 odours) of the UPSIT were administered to each nasal chamber of the test subjects by a trained test administrator who released the stimuli under each subject's nose, read aloud the response alternatives, and recorded the responses. The nostril contralateral to the one being tested was comfortably but

tightly sealed with a piece of MicrofoamTM tape (3M Corporation, Minneapolis, MN) fitted to the perimeter of the naris. The tape insured that nasal inhalation occurred only on one side of the nose and precluded active retronasal movement of air to the receptors of the contralateral nasal chamber.³³ The testing order of the nares and the presentation order of the UPSIT booklets was counterbalanced across subjects.

Assessment of cognitive function

All of the PD patients were given the 40 item Picture Identification Test (PIT), a forced choice visual test identical to the UPSIT except that line drawings, rather than odours, are used as stimulus items.³⁴ This test is specifically designed to screen for patients whose aberrant UPSIT scores might be due to problems in comprehending non-olfactory components of the test rather than to problems in olfactory perception. The PIT correlates well with a number of neuropsychological measures and is sensitive to dementia-related cognitive deficits, as described elsewhere.⁷

Assessment of neurological function

Patients were staged according to the Hoehn and Yahr scale.³⁵ The degree of tremor (left and right upper extremities), rigidity (left and right upper extremities), bradykinesia, and gait disturbance was rated on a standardised 4-point rating scale (0 = absent; 4 = severe) by neurologists with expertise in extrapyramidal disorders (MBS, HIH, SMG). With the exception of a single stage III patient, all patients were either stage I (25) or stage II (14).

Results

Relative to normal controls, both the treated and untreated PD patients showed decreased olfactory function on both sides of the nose (table 2). Because several PD patients had severe olfactory dysfunction, data are presented separately in table 2 for those patients whose total UPSIT score (L + R) was greater than 20 to establish whether systematic decreases in the test scores for one or the other side of the nose might be confined to cases with a better sense of smell. No significant left:right differences in the test scores were found (regardless of disease stage or level of olfactory functioning), and the test scores were unrelated to the side of PD-related motor disturbance and not significantly influenced by the use of anti-Parkinsonian drugs (all p values > 0.10). No consistent relation was observed between the subjects' handedness and the asymmetry in the average test measures (for example, for right handed subjects the mean (SD) left and right UPSIT scores were 11.03 (4.40) and 10.56 (4.18); analogous scores for left-handers 12.67 (3.98) and 11.33 (4.13)), although the small number of left handed subjects (six) precluded a definitive statistical test of this issue. As expected, however, on the basis of previous studies^{6,7} the PD patients exhibited clear olfactory dysfunction not attributable to non-olfactory related cognitive problems (that

Table 2 Mean (SD) University of Pennsylvania Smell Identification Test (UPSIT) scores for untreated and treated patients with Parkinsonism and normal controls. Dominant side is major body side of primary PD-related motor symptoms. Each nasal chamber was tested with 20 UPSIT items (total possible score 20)

	Untreated patients	Treated patients	Normal controls
<i>All subjects</i>			
Left side UPSIT	11.40 (4.38) ^a	11.15 (4.39) ^a	16.50 (2.28)**
Right side UPSIT	10.80 (4.57) ^a	10.55 (3.75) ^a	16.20 (3.07)**
Dominant side UPSIT	11.47 (4.53) ^b	10.60 (3.53) ^a	
Nondominant side UPSIT	11.11 (4.52) ^b	11.10 (4.58) ^a	
<i>All patients with L plus R UPSIT scores > 20</i>			
Left side UPSIT	14.50 (2.39) ^c	13.62 (3.33) ^d	
Right side UPSIT	13.83 (3.19) ^c	12.39 (2.93) ^d	
Dominant side UPSIT	14.42 (2.58) ^c	12.31 (2.81) ^d	
Nondominant side UPSIT	13.92 (3.06) ^c	13.69 (3.40) ^d	
<i>Stage I patients only</i>			
Left side UPSIT	10.90 (4.15) ^e	10.80 (5.00) ^e	
Right side UPSIT	10.80 (4.10) ^e	11.30 (4.32) ^e	
Dominant side UPSIT	11.44 (4.19) ^f	11.30 (3.83) ^e	
Nondominant side UPSIT	11.00 (4.18) ^f	10.80 (5.39) ^e	
<i>Stage I patients with L plus R UPSIT scores > 20</i>			
Left side UPSIT	13.67 (2.42) ^g	15.00 (3.39) ^h	
Right side UPSIT	13.67 (2.16) ^g	14.60 (2.88) ^h	
Dominant side UPSIT	13.83 (2.32) ^g	14.20 (2.78) ^h	
Nondominant side UPSIT	13.50 (2.26) ^g	15.40 (3.36) ^h	

^an = 20; ^bn = 19; ^cn = 12; ^dn = 13; ^en = 10; ^fn = 9; ^gn = 6; ^hn = 5.

*Indicates controls differed significantly from each of the PD groups (p values < 0.001; see text), which did not differ from one another. Analogous tests between untreated and treated groups were not significant in any subject category (p values > 0.10).

is, all but five scored 40/40 on the PIT; the remainder missed three or fewer items). Thus, the left and right side UPSIT scores of the controls were significantly higher than the left and right side UPSIT scores of the two patient groups (group $\times$ gender ANCOVA; covariate = age; group F_s (1,55) = 7.69 & 9.51, p values = 0.008 and 0.003), which in no case differed significantly from one another (post hoc comparison p values > 0.20). Women, on average, obtained higher UPSIT scores than men, regardless of the side of nose tested (left and right UPSIT gender F_s (1,55) = 5.55 and 3.86, p values = 0.022 and 0.054; mean (SD) left and right UPSIT scores for male and female PD patients and the male and female normal controls, respectively: 10.23 (4.03), 10.00 (4.16), 13.78 (4.35), 13.22 (4.68), 16.33 (2.09), 15.73 (3.28), 17.00 (3.00), and 17.60 (1.95)). Analogous ANCOVAs between the untreated and treated PD groups yielded no significant group F values in any subject category (p > 0.10), although in most cases significant gender effects were observed (p values < 0.05).

Most of the PD patients showed UPSIT scores on each side of the nose that were equivalent or relatively close to one another. Thus, 15% had equivalent scores on each side of the nose, 30% had scores differing by one UPSIT point, and 20% had scores differing by two UPSIT points. Scores differing by three, four, five and six UPSIT points were noted in the remaining 12.5%, 12.5%, 5%, and 5% of the PD subjects, respectively. For the study group as a whole these differences were, on average, symmetrical (median (interquartile range) asymmetry value = 0 (−1 to +2.5), where negative numbers indicate larger right side values and positive numbers larger left side values). This average lack of asymmetry was also observed for the normal subjects where the median asymmetry value also was equal to 0 (−3 to +2.5). No meaningful associations were observed between the direction of the asymmetries in the PD patients and the side of the major PD symptoms, even in those subjects

who evidenced the largest apparent olfactory asymmetries.

Few of the correlations computed among the variables (for example, gender, age, smoking status, Hoehn and Yahr stage, neurological ratings) for the PD groups combined were significant at p = 0.05 (Bonferroni's correction for inflated alpha).³⁶ Nevertheless, significant correlations were observed among the various olfactory measures (for example, left UPSIT v right UPSIT r = 0.81; dominant side UPSIT v nondominant side UPSIT r = 0.80) and among several neurological measures (for example, disease duration v right rigidity r = 0.48; gait v bradykinesia = 0.57; left rigidity v left tremor r = 0.60). The pattern of associations between the variables was similar to that observed in earlier studies,^{6,7} as shown by factor loadings extracted with a principal components factor analysis with a varimax rotation.³⁰ Because of this similarity, the details of the factor analysis are not presented here.

As in our earlier work,⁶ each patient was asked whether he or she suffered from any smell or taste problems before olfactory testing. Four men and one woman within the untreated group and two men and two women within the treated group indicated that they had such problems (22.5%). Those aware of a smell problem before testing had lower UPSIT test scores than those who were unaware, also in accord with our earlier findings (respective means (SD): left side 8.44 (3.25) v 11.84 (11.23); right side 9.00 (2.65) v 11.23 (4.36); left plus right sides 17.44 (5.03) v 23.07 (8.42); respective ANCOVA (covariates gender and age) group F values (1,35) = 5.40 (p = 0.03), 4.36 (p = 0.04), 5.51 (p = 0.03)).

Discussion

Our results show that the olfactory deficit observed in early PD is not secondary to the use of anti-Parkinsonian drugs and, for a given subject, is relatively similar on both sides of the nose. Although modest asymmetries were

present in the test scores of some of the PD patients, no relation was observed between the direction or magnitude of such asymmetries and the side of the motor dysfunction of hemi-Parkinsonism. Importantly, the median olfactory asymmetry value of the PD patients was zero and the range of asymmetry values fell within that observed for normal subjects. As in the case of several other disorders in which olfaction is impaired,³⁷ PD-related olfactory dysfunction was found to be less in women than in men. The basis of the olfactory dysfunction of PD is unknown, although it could reflect a PD-related vulnerability of the olfactory system to destruction by environmental factors or PD-related retrograde degenerative processes. Several theorists have proposed that some forms of Parkinsonism and other neurodegenerative disorders, such as Alzheimer's disease, may be caused by the entry of environmental agents or toxins from the nasal cavity into the brain.^{38,39} The entry of viruses from the nasal cavity into the CNS is a well documented phenomenon,⁴⁰⁻⁴⁴ and several large macromolecules can readily enter the CNS of rodents and other animals from the nose.⁴⁵⁻⁴⁸ PD may be associated with a breakdown of the mucosal barrier which normally detoxifies xenobiotic agents and prevents them from damaging the olfactory membrane or from entering into the CNS via the olfactory receptors or surrounding mucosal tissue.⁴⁹ Germane to this notion are observations that nasal tissues contain very high concentrations of enzymes that metabolise xenobiotics (for example, cytochromes P-450, flavin containing monooxygenase and aldehyde dehydrogenases, and carboxylesterases);⁵⁰⁻⁵² metabolic rates for xenobiotics within nasal tissue typically exceed those of other extrahepatic tissues and commonly exceed those of the liver;⁵³ and PD patients are less likely to detoxify drugs by sulphation or sulfoxidation than are similarly exposed controls.⁵⁴

Whatever the basis for the olfactory dysfunction in PD, our patients showed average total UPSIT scores (L plus R UPSIT values) which, for all practical purposes, were equivalent to the bilateral UPSIT scores of PD patients reported in earlier work (respective means (SD) 21.95 (8.05) *v* 20.83 (7.44)).⁶ This is in spite of the fact that all but one of the present subjects were at Hoehn and Yahr stage I or stage II of the disease process (compared to about half the subjects in the earlier study) and that nearly all had Parkinsonian symptoms for a much shorter period of time (respective symptom duration means in years (SD) 5.0 (3.3) *v* 12.4 (10.1)). While these similarities are most likely a reflection of similar degrees of olfactory pathology within the two groups and the independence of the UPSIT scores from disease stage and duration, two factors may have had some differential influence on the test scores. Firstly, our patients were nearly five years younger than those in the earlier study (61.95 *v* 66.35 years) and UPSIT scores are known to decline several points over this age period.^{27,31} Secondly, bilateral UPSIT testing, on average, tends to result in slightly higher UPSIT scores than unilateral testing (for

example, the L plus R UPSIT score obtained from unilateral administration in eight PD subjects of the present study who had UPSIT scores > 18 was significantly lower than the bilateral UPSIT score obtained from these same individuals; respective means (SD) 26.63 (9.15) *v* 29.13, *t* = 3.50, *p* = 0.024). Presumably these effects offset one another to about the same degree.

Supported by grant RO1 AG 08148 from the National Institute on Aging and grant PO1 DC 00161 from the National Institute on Deafness and Other Communication Disorders. We thank Kathy Shallow and the other members of the staff of the neurology department of Graduate Hospital for their assistance in data collection and Richard Frye and John Pierce for comments on an earlier version of the manuscript.

- Doty RL, Reyes P, Gregor T. Presence of both odor identification and detection deficits in Alzheimer's disease. *Brain Res Bull* 1987;18:597-600.
- Knupper L, Spiegel R. Differences in olfactory test performance between normal aged, Alzheimer and vascular type dementia individuals. *Internat J Geriatr Psychiat* 1986; 1:3-14.
- Warner MD, Peabody CA, Flattery JJ, *et al*. Olfactory deficits and Alzheimer's disease. *Biol Psychiat* 1986; 21:116-8.
- Anasari KA, Johnson A. Olfactory function in patients with Parkinson's disease. *J Chron Dis* 1975;28:493-7.
- Walden S. Clinical observations of impaired cranial nerve function in senile dementia. *Acta Psychiat Scand* 1974; 50:539-47.
- Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration. *Neurology* 1988; 38:1237-44.
- Doty RL, Riklan M, Deems DA, Reynolds C, Stellar S. The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. *Ann Neurol* 1989;25:166-71.
- Serby M, Corwin J, Conrad P, Rotrosen J. Olfactory dysfunction in Alzheimer's disease and Parkinson's disease. *Amer J Psychiat* 1985;142:781-2.
- Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1987;50:88-9.
- Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. *Neurology* 1983;33:943-6.
- Doty RL, Perl DP, Steele JC, *et al*. Odor identification deficit of the parkinsonism-dementia complex of Guam: equivalence to that of Alzheimer's and idiopathic Parkinson's disease. *Neurology* 1991;41(suppl 2):77-80.
- Averback P. Two new lesions in Alzheimer's disease. *Lancet* 1983;ii:1204.
- Esiri MM, Wilcock PK. The olfactory bulb in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 1984;47:56-60.
- Hooper MW, Vogel FS. The limbic system in Alzheimer's disease. *Amer J Pathol* 1976;85:1-13.
- Ohm TG, Braak H. Olfactory bulb changes in Alzheimer's disease. *Acta Neuropathologica* 1987;73:365-9.
- Pearson RCA, Esiri MM, Hiorns RW, Wilcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. *Proc Nat Acad Sci USA* 1985;82:4531-4.
- Reyes PF, Golden GT, Fagel PL, *et al*. The prepiriform cortex in dementia of the Alzheimer type. *Arch Neurol* 1987;50:113-5.
- Talamo BR, Rudel R, Kosik KS, *et al*. Pathological changes in olfactory neurons in patients with Alzheimer's disease. *Nature* 1989;337:736-9.
- Hirano A, Zimmerman HM. Alzheimer's neurofibrillary changes. A topographic study. *Arch Neurol* 1962;7: 227-42.
- Perl DP, Levy D, Steele JC, Loerzel JA, Good PF, Doty RL. Severe neuronal loss in the anterior olfactory nucleus (AON) in parkinsonism-dementia complex (PDC) of Guam. *Neurology* 1990;40(suppl 1):405.
- Koelega HS. Olfaction and sensory asymmetry. *Chem Senses Flav* 1979;4:89-95.
- Eskenazi B, Cain WS, Novelty RA, Mattson R. Odor perception in temporal lobe epilepsy patients with and without temporal lobectomy. *Neuropsychologia* 1986; 24:553-62.
- Bentin S, Silverberg R, Gordon HW. Asymmetrical cognitive deterioration in demented and Parkinson patients. *Cortex* 1981;17:533-44.
- Direnfeld LK, Albert ML, Volicer L, Langlais PJ, Marquis J, Kaplan E. Parkinson's disease: the possible relationship of laterality to dementia and neurochemical findings. *Arch Neurol* 1984;41:935-41.
- Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. *New Engl J Med* 1989;321:1364-71.
- Doty RL, Shanan P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. *Physiol Behav* (Monograph) 1984;32:489-502.

- 27 Doty RL, Shaman P, Applebaum SL, Giberson R, Sikorsky L, Rosenberg L. Smell identification ability: changes with age. *Science* 1984;226:1441-3.
- 28 Doty RL, Applebaum SL, Zusho H, Settle RG. A cross-cultural study of sex differences in odor identification ability. *Neuropsychologia* 1985;23:667-72.
- 29 Frye RE, Schwartz B, Doty RL. Dose-related effects of cigarette smoking on olfactory function. *J Amer Med Assoc* 1990;263:1233-6.
- 30 Wilkinson L. *SYSTAT: the system for statistics*. Evanston, IL: SYSTAT Inc, 1987.
- 31 Doty RL. *The Smell Identification Test™ administration manual*. (2nd ed.) Haddonfield, Senonics, 1989.
- 32 Doty RL, Ugrawal U, Frye RE. Evaluation of the internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test (UPSIT). *Percept Psychophys* 1989;45:381-4.
- 33 Burdach K, Doty RL. Retronasal flavor perception: influences of mouth movements, swallowing and spitting. *Physiol Behav* 1987;41:353-6.
- 34 Vollmecke T, Doty RL. Development of the Picture Identification Test (PIT): A research companion to the University of Pennsylvania smell identification test. *Chem Senses* 1985;10:413-4.
- 35 Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. *Neurology* 1967;17:427-42.
- 36 Myers JL. *Fundamentals of experimental design* (3rd ed.). Boston: Allyn and Bacon, 1979.
- 37 Deems DA, Doty RL, Settle RG, et al. Smell and taste disorders, A study of 750 patients from the University of Pennsylvania smell and taste center. *Arch Otolaryngol Head Neck Surg* 1991;117:519-28.
- 38 Harrison PJ. Pathogenesis of Alzheimer's disease—beyond the cholinergic hypothesis: discussion paper. *J Roy Soc Med* 1986;79:347-52.
- 39 Roberts R. Alzheimer's disease may begin in the nose and may be caused by aluminosilicates. *Neurobiol Aging* 1986;7:561-7.
- 40 Barthold SW. Olfactory neural pathway in mouse hepatitis virus nasoencephalitis. *Acta Neuropathol* 1988;76:502-6.
- 41 Lundh B, Kristensson K, Norrby E. Selective infections of olfactory and respiratory epithelium by vesicular stomatitis and sendai viruses. *Neuropathol Appl Neurobiol* 1987;13:111-22.
- 42 Monath TP, Croop CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system: reinvestigation of an old controversy. *Lab Invest* 1983;48:399-410.
- 43 Morales JA, Herzog S, Kompter C, Frese K, Rott R. Axonal transport of Borna disease virus along olfactory pathways in spontaneously and experimentally infected rats. *Med Microbiol Immunol* 1988;177:51-68.
- 44 Tomlinson AH, Esiri MM. Herpes simplex encephalitis: immunohistological demonstration of spread of virus via olfactory pathways in mice. *J Neurol Sci* 1983;60:473-84.
- 45 Perl DP, Good PF. Uptake of aluminum into central nervous system along nasal-olfactory pathways. *Lancet* 1987; i:1028.
- 46 Shipley MT. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. *Brain Res Bull* 1985;15:129-42.
- 47 Baker H, Spencer RF. Transneuronal transport of peroxidase conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of adult rat. *Exp Brain Res* 1986;63:461-73.
- 48 Cancelon P, Beidler LM. Distribution along the axon and into various subcellular fractions of molecules labeled with ³H leucine and rapidly transported in the garfish olfactory nerve. *Brain Res* 1975;89:225-44.
- 49 Doty RL. Olfactory dysfunction in neurodegenerative disorders. In: Getchell TV, Doty RL, Bartoshuk LM, Snow Jr JB, eds. *The chemical senses in health and disease*. New York: Raven, 1991:735-51.
- 50 Dahl AR. Selective activation of carcinogens and other toxicants by nasal mucosae. In: Paton W, Mitchell J, Turner P, eds. *Proceedings of the Ninth IUPHAR Congress of Pharmacology*, Vol 1. London: Macmillan, 1985:203-8.
- 51 Dahl AR. Activation of carcinogens and other xenobiotics by nasal cytochromes P-450. In: Boobis AR, Caldwell J, DeMatteis F, Elcombe CR, eds. *Microsomes and drug oxidations*. Philadelphia: Taylor and Francis, 1985: 299-309.
- 52 Dahl AR. Possible consequences of cytochrome P-450-dependent mono-oxygenases in nasal tissues. In: Borrows CS, ed. *Toxicology of the nose*. Research Triangle Park, NC: Chemical Industry Institute for Toxicology, 1985: 263-71.
- 53 Dahl AR. The effect of cytochrome P-450-dependent metabolism and other enzyme activities on olfaction. In: Margolis FL, Getchell TV, eds. *Molecular neurobiology of the olfactory system*. New York: Plenum Press, 1988: 51-70.
- 54 Stevenon GB, Heafield MTC, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. *Neurology* 1989;39:883-7.